415 results on '"Nanni, Patrizia"'
Search Results
2. Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
3. Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
4. Immunoprevention
5. Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy
6. Chapter Five - Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay
7. Data from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
8. Figure S1 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
9. Supplementary Materials and Methods from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
10. Table S2 from A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy
11. Supplementary Figure 1 from In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
12. Supplementary Figure 5 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
13. Supplementary Figure S1 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
14. Data from In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
15. Data from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
16. Supplementary Figure Legend from In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
17. Data from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
18. Supplementary Table 1 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
19. Supplementary Figure 3 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
20. Supplementary Figure 2 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
21. Supplementary Methods from In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
22. Supplementary Table 4 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
23. Supplementary Table 3 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
24. Supplementary Figure 1 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
25. Supplementary methods, figure legends and references from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
26. Data from Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine
27. Supplementary Figure 4 from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
28. Supplementary Table 2 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
29. Supplementary Tables 1-4 from In silico Modeling and In vivo Efficacy of Cancer-Preventive Vaccinations
30. Supplementary Figure from Immunoprevention of HER-2/neu Transgenic Mammary Carcinoma through an Interleukin 12-Engineered Allogeneic Cell Vaccine
31. Supplementary Methods and Figure Legends from A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function
32. Re: Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study
33. Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
34. Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis
35. Immunoprevention
36. ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged NSCLC
37. Immunoprevention
38. Cancer immunoprevention: from mice to early clinical trials
39. Inhibition of Human Tumor Growth in Mice by an Oncolytic Herpes Simplex Virus Designed to Target Solely HER-2-positive Cells
40. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy
41. Immunoprevention
42. HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
43. 2011: the immune hallmarks of cancer
44. Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment
45. Preclinical vaccines against mammary carcinoma
46. Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis
47. Vaccines for tumour prevention
48. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario
49. IFN-γ and CD38 in Hyperprogressive Cancer Development
50. Modeling the competition between lung metastases and the immune system using agents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.